Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ashton William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 25,000 options Underlying shares: 25,000 shares Exercise price: $0.50 per share +2 more

5 metrics

Options granted 25,000 options Stock Option (right to buy) grant

Underlying shares 25,000 shares Common Shares underlying the option grant

Exercise price $0.50 per share Conversion or exercise price of the options

Expiration date March 27, 2031 Option expiration date

Options after transaction 25,000 options Total derivative shares following transaction

Key Terms

Stock Option (right to buy), exercise price, derivative, grant, award, or other acquisition

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.5000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashton William

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) director Ashton William report?

Director Ashton William reported receiving a grant of stock options for 25,000 underlying common shares. These options represent a compensation award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many Medicus Pharma (MDCX) shares are covered by the new options?

The new option grant covers 25,000 underlying common shares of Medicus Pharma. This means he can choose to buy up to 25,000 shares under the terms of the option agreement, subject to the specified exercise price and expiration date.

What is the exercise price of Ashton William’s Medicus Pharma (MDCX) options?

The exercise price of the options is $0.50 per share. This is the fixed price at which he can purchase Medicus Pharma common shares through the option grant, regardless of the market price when he exercises, if he chooses to do so.

When do Ashton William’s Medicus Pharma (MDCX) options expire?

The stock options reported by Ashton William expire on March 27, 2031. After that expiration date, any unexercised options become worthless and can no longer be used to acquire Medicus Pharma common shares under this grant.

Is Ashton William’s Medicus Pharma (MDCX) option grant a market buy or sell?

The filing shows a grant or award acquisition, not a market buy or sell. The options were awarded at no cost as part of compensation, giving him the right to purchase shares later at $0.50 per share if he chooses.